Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Weighted Average)
Others
Ratios

Immuneering (IMRX) Income from Continuing Operations: 2020-2023

Historic Income from Continuing Operations for Immuneering (IMRX) over the last 4 years, with Dec 2023 value amounting to -$15.5 million.

  • Immuneering's Income from Continuing Operations fell 15.44% to -$15.5 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$54.8 million, marking a year-over-year decrease of 8.03%. This contributed to the annual value of -$54.8 million for FY2023, which is 8.50% down from last year.
  • According to the latest figures from Q4 2023, Immuneering's Income from Continuing Operations is -$15.5 million, which was down 18.95% from -$13.1 million recorded in Q3 2023.
  • In the past 5 years, Immuneering's Income from Continuing Operations registered a high of -$3.2 million during Q2 2020, and its lowest value of -$15.5 million during Q4 2023.
  • For the 3-year period, Immuneering's Income from Continuing Operations averaged around -$11.6 million, with its median value being -$12.6 million (2022).
  • Data for Immuneering's Income from Continuing Operations shows a maximum YoY tumbled of 149.56% (in 2021) over the last 5 years.
  • Immuneering's Income from Continuing Operations (Quarterly) stood at -$5.8 million in 2020, then crashed by 88.02% to -$11.0 million in 2021, then declined by 22.75% to -$13.5 million in 2022, then fell by 15.44% to -$15.5 million in 2023.
  • Its last three reported values are -$15.5 million in Q4 2023, -$13.1 million for Q3 2023, and -$12.3 million during Q2 2023.